Delving into the Latest Updates on NB-001(BlueWillow Biologics) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action

modulators

Mechanism

Cell membrane modulators

Therapeutic Areas

Infectious DiseasesMouth and Tooth DiseasesSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Herpes Labialis

Originator Organization

BlueWillow Biologics, Inc.

Active Organization-

Inactive Organization

BlueWillow Biologics, Inc.

License Organization-

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

This is a study to test the hypothesis that time to healing of a cold sore will be lower in the active treatment arm of the study when compared to the vehicle (placebo). Subjects with a history of cold sores will be enrolled and administered active treatment or placebo in a blinded manner. Subjects will then be followed to assess time to healing.

Start Date01 Oct 2012

Sponsor / Collaborator

BlueWillow Biologics, Inc.

NCT01324466

/ CompletedPhase 3

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis

The purpose of this study is to demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).

Start Date01 Apr 2011

Sponsor / Collaborator

BlueWillow Biologics, Inc.

NCT01321359

/ CompletedPhase 3